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Abstract
Background: Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes.
Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to
treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only
responds transiently to imatinib therapy, we have used mouse models to test the efficacy of
nilotinib against lymphoblastic leukemia caused by the P190 form of Bcr/Abl.
Results: After transplant of 10,000 highly malignant leukemic cells into compatible recipients,
untreated mice succumbed to leukemia within 21 days, whereas mice treated with 75 mg/kg
nilotinib survived significantly longer. We examined cells from mice that developed leukemia while
under treatment for Bcr/Abl kinase domain point mutations but these were not detected. In
addition, culture of such cells ex vivo showed that they were as sensitive as the parental cell line to
nilotinib but that the presence of stromal support allowed resistant cells to grow out. Nilotinib also
exhibited impressive anti-leukemia activity in P190 Bcr/Abl transgenic mice that had developed
overt leukemia/lymphoma masses and that otherwise would have been expected to die within 7
days. Visible lymphoma masses disappeared within six days of treatment and leukemic cell numbers
in peripheral blood were significantly reduced. Treated mice survived more than 30 days.
Conclusion: These results show that nilotinib has very impressive anti-leukemia activity but that
lymphoblastic leukemia cells can become unresponsive to it both in vitro and in vivo through
mechanisms that appear to be Bcr/Abl independent.
Background
The Philadelphia chromosome (Ph) is present in about
5% of childhood acute lymphoblastic leukemia (ALL) and
20–30% of adult ALL [1]. The Ph-chromosome is pro-
duced by a reciprocal translocation t(9;22) between chro-
mosomes 9 and 22. The translocation results in the
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generation of a BCR/ABL fusion gene in which the ABL
protooncogene on chromosome 9 is fused to segments of
the  BCR  gene. Depending upon where the breakpoint
occurs in the BCR locus, two alternate products, P210 or
P190 Bcr/Abl fusion proteins can be translated. P210 is
predominantly associated with chronic myeloid leukemia
(CML), whereas the P190 form is mainly associated with
Philadelphia positive ALL [2,3].
The deregulated tyrosine kinase activity of Bcr/Abl is
essential for Bcr/Abl mediated transformation [4-6], and
imatinib, an inhibitor of the Bcr/Abl tyrosine kinase [7], is
widely used clinically for treating Ph-positive leukemias
[8]. Imatinib is a very effective therapy for chronic phase
CML [9,10]. However, patients in the accelerated phase or
blast crisis of CML respond poorly and resistance fre-
quently emerges [11-21]. Additionally, Ph-positive ALL
has a poor prognosis even with imatinib treatment
[22,23].
New inhibitors for Bcr/Abl are under development. Weis-
berg et al [24] first described experiments testing Nilotinib
(Tasigna™; AMN107; Novartis Pharma AG), which was
designed to improve potency and selectivity by incorpo-
rating alternate binding groups to the backbone of imat-
inib. In preclinical models of CML, nilotinib was
confirmed to be much more potent than imatinib and
also active against 32 of 33 Bcr/Abl mutant forms that are
imatinib-resistant [24-28]. However, additional nilotinib-
resistant Bcr/Abl mutants can be generated in vitro, in
addition to the known T315I imatinib-resistant mutant
[29-32].
The reason for the poor response of Ph+ ALL towards
imatinib therapy is unclear. To date, nilotinib has only
been tested in vitro on human Ph-positive ALL cells and on
Bcr/Abl-transfected 32D and BaF3 cells [24,26]. Nilotinib
was also used in phase I clinical trails for CML and for
treatment of a very small number of Ph-positive ALL
patients [25]. To better understand the effectiveness of
new therapies and the mechanisms of resistance in Ph-
positive ALL, we generated a transgenic Bcr/Abl P190
mouse model for lymphoblastic leukemia [33,34]. In the
current study, we tested the efficacy of nilotinib both in
vitro and in vivo as monotherapy to eradicate P190 Bcr/Abl
lymphoblastic leukemia cells. We conclude that nilotinib
is very effective in these settings in killing P190 Bcr/Abl
lymphoblastic leukemia cells but that resistance can
develop.
Results
Treatment with nilotinib of lymphoblastic leukemia cell 
lines
Nilotinib has been reported to be more potent than imat-
inib in inhibiting the proliferation of Bcr/Abl expressing
cells [24-28]. To study its effectiveness in eliminating lym-
phoblastic leukemia cells in vitro, we compared 8093 lym-
phoblastic leukemia cells treated with different
concentrations of nilotinib to the same cells treated with
5 µM imatinib. As shown in Fig. 1A, at the start of the drug
treatment, all 8093 cells had a viability of >90%. Within
Comparative effect of nilotinib and imatinib on viability of  three different lymphoma cell lines Figure 1
Comparative effect of nilotinib and imatinib on via-
bility of three different lymphoma cell lines. (A), 8093; 
(B), B-1; (C), B-2. 3 × 106 lymphoma cells were seeded on 6-
well tissue culture plates in the presence of E14.5 irradiated 
MEFs and cultured for 3 days. All cultures were simultane-
ously treated with the indicated concentrations of nilotinib 
or imatinib. Viability is defined as the percentage of viable 
cells/of the total number of cells. Each point represents mean 
of triplicate values ± standard error of the mean.
0
20
40
60
80
100
02 44 8 7 2
50 nM nilotinib
100 nM nilotinib
200 nM nilotinib
5u Mi m a t i n i b
0
20
40
60
80
100
0 2 44 87 2
20 nM nilotinib
50 nM nilotinib
100 nM nilotinib
1u Mi m a t i n i b
0
20
40
60
80
100
02 4 4 8 7 2
100 nM nilotinib
200 nM nilotinib
500 nM nilotinib
5u Mi m a t i n i b
viability
(%)
hours
A
B
C
viability
(%)
hours
viability
(%)
hoursMolecular Cancer 2007, 6:67 http://www.molecular-cancer.com/content/6/1/67
Page 3 of 11
(page number not for citation purposes)
24 hours of treatment, this dropped to less than 45%
under all treatment conditions. The effect of nilotinib
treatment on cell viability was dose-dependent. 200 nM
nilotinib treatment reduced the viability of the 8093 cul-
ture from >90% to 18% within 24 hours whereas treat-
ment with 100 nM reduced viability to 28% within 24
hours. A lower dose of 50 nM left about 40% of the cells
viable after the same time period. Cell viability was
reduced to zero within 72 hours for all three concentra-
tions of nilotinib.
This result showed that nilotinib is very efficient in eradi-
cating a large number of leukemia cells. In comparison, 5
µM imatinib treatment was about as effective as the 200
nM nilotinib treatment (cell viability reduced to 18% and
13%, respectively after 24 hrs). We also compared the
effect of nilotinib to that of imatinib in two other inde-
pendent lines established from two different P190 Bcr/Abl
transgenic mice. As shown in Fig. 1B and Fig. 1C, the exact
degree of sensitivity differed among the three cell lines,
although in all, nilotinib was more effective than imat-
inib. Overall, we found that nilotinib is 10–25 fold more
potent than imatinib, suggesting great potential for in vivo
therapy.
Treatment with nilotinib in a transplant model
The effect of nilotinib has not been evaluated in mouse
models of Ph-positive ALL. To examine the effectiveness
of nilotinib treatment in vivo, fifteen C57Bl/6J mice were
transplanted via a tail vein injection with 104 8093 cells.
Nilotinib treatment (7 mice) or control treatment (8
mice) was started five days after transplantation. The dose
of 75 mg/kg daily was chosen based on previous studies
using mouse cell lines transfected with Bcr/Abl P210 and
transplanted into nude mice [24]. They showed, that at
this concentration, the drug was well absorbed and bioa-
vailable for up to 24 hours.
Vehicle treated mice became moribund within 3 weeks of
the transplantation. They showed clear symptoms of ALL.
Nilotinib-treated mice lived statistically significantly
longer as compared with the vehicle-treated mice (p <
0.05)(Fig. 2). This result clearly indicated that nilotinib
was very effective in inhibiting the proliferation of the
leukemic cells in vivo. However, also five of the seven
drug-treated mice died. We ended treatment of the two
remaining mice 51 days after the transplant of the leuke-
mic cells, when all vehicle-treated mice had died. At this
point both appeared normal. However, these two mice
succumbed to leukemia 8 and 14 days later.
Treatment of leukemic Bcr/Abl P190 transgenic mice
In this transplant model, the initiation of leukemia is syn-
chronized and the drug is tested for effect against an ini-
tially small number of highly malignant cells. The P190
Bcr/Abl transgenic mice represent a different model of
leukemia. The disease has a natural progression, starting
with an initial phase in which mice are healthy. On a
C57Bl/6J background, mice become overtly sick when
they are, on average, 100 days old. To study the effect of
nilotinib treatment on this more natural model of
advanced stage leukemia, we randomly selected five P190
Bcr/Abl mice showing visible signs of lymphoma and
nilotinib treatment of 75 mg/kg daily was started.
Remarkably, nilotinib treatment led to a complete regres-
sion of the overt lymphomas within six days for all five
Bcr/Abl transgenic mice (Fig. 3A). A significant improve-
ment in the health of all five mice was also observed, with
increased activity and restored mobility within one week
of treatment. We treated the five mice for a total of 30 days
(Fig. 3B). Two of the mice that were taken off treatment
died 11 days later, whereas three mice survived more than
50 days without visible reoccurrence of the leukemia/lym-
phoma. Five additional Bcr/Abl transgenic mice were
selected upon visible signs of lymphoma and were kept
under observation without any treatment. All five mice in
the untreated group became moribund within 3–11 days
and were sacrificed according to institutional regulations
(Fig. 3B).
We analyzed cells from preleukemic, leukemic and con-
trol wild type mice for cell surface markers suitable to
detect the leukemic cells. CD19 was chosen as a general B
cell antigen and AA4.1 as an antigen to distinguish mature
B cells (AA4.1low) from immature B cell precursors
Nilotinib is very effective in the treatment of Bcr/Abl-caused  lymphoblastic leukemia in vivo Figure 2
Nilotinib is very effective in the treatment of Bcr/
Abl-caused lymphoblastic leukemia in vivo. Survival of 
C57Bl/6J mice transplanted with 8093 lymphoma cells and 
treated either with nilotinib (n = 7; 75 mg/kg daily) or with 
vehicle (n = 8). Nilotinib-treated mice lived significantly (p < 
0.01) longer than the control group.
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Analysis of nilotinib in a transgenic mouse model of terminal leukemia/lymphoma Figure 3
Analysis of nilotinib in a transgenic mouse model of terminal leukemia/lymphoma. (A), Five P190 Bcr/Abl trans-
genic mice were treated with 75 mg/kg nilotinib daily upon visible signs of lymphoma for a period of 30 days. This image shows 
one of the five mice treated with the drug. Arrows point to the dramatic reduction in the size of the lymph node swelling/lym-
phoma over a period of six days of treatment. (B), Survival after diagnosis of overt leukemia/lymphoma. Numbers to the left 
indicate individual identifiers of the transgenic mice. The arrow points to the first diagnosis of leukemia/lymphoma. The black 
line represents time to leukemia (days), the grey bars the period of treatment with nilotinib and the white bars time to death 
after no treatment. (C), Peripheral blood of two wild type (Wt) littermates; two overtly leukemic P190 Bcr/Abl transgenic 
mice before treatment and the same mice after 7 days of 75 mg/kg nilotinib treatment. Dead cells were excluded based on pro-
pidium iodide uptake and the analysis was restricted to living mononuclear cells by forward and side scatter gate settings. Anti-
bodies are as indicated. (D), Percentage of peripheral blood cells that had cell surface expression of CD19 and high levels of 
AA4.1. Bars, ± SEM. Wild type, n = 3; preleukemic, n = 3; leukemic, n = 3; nilotinib-treated, n = 2.Molecular Cancer 2007, 6:67 http://www.molecular-cancer.com/content/6/1/67
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(AA4.1high; ref. [35]). AA4.1high B cells are very rare in the
peripheral blood (PB) of normal mice (Fig. 3C, left panels
and Fig. 3D). Whereas in the normal mice, the percentage
of CD19+ cells in PB was low, the PB of the leukemic ani-
mals consisted almost entirely of CD19+ cells, of which
the majority was AA4.1high (Fig. 3C, middle panel, Fig.
3D). When these animals were treated for only seven days
with nilotinib, the numbers of these CD19+AA4.1high
leukemic cells were substantially reduced and other cells
re-appeared in the peripheral blood (Fig. 3C, right panel).
We also quantitated the numbers of leukemic cells in the
PB of the mice. Whereas the PB of preleukemic animals
contained low but detectable numbers (mean, around
0.7% of the total WBC), the overtly leukemic animals had
large amounts (mean 75% of the total WBC) of such cells
in the circulation. Treatment for only 7–8 days with nilo-
tinib had a very significant impact on the leukemic cell
numbers, reducing them to levels (0.9% of the total WBC)
comparable to that found in a wild type mice (Fig. 3D).
Thus, these results clearly showed that nilotinib was also
very effective in treating advanced stage leukemia.
Effect of nilotinib on Bcr/Abl tyrosine kinase activity
During the course of treatment with nilotinib, five out of
the seven mice that had been transplanted with the 8093
leukemia cells developed symptoms of lymphoma and
were sacrificed. To determine to what extent nilotinib was
able to inhibit the Bcr/Abl kinase activity when the mice
started showing symptoms of ALL, we sacrificed two of the
five mice in the nilotinib treatment group 23 hours after
the last nilotinib administration and three within two
hours of drug treatment. SDS-SB tissue lysates of lympho-
mas isolated from the animals were prepared for each of
the five animals. We also grew the lymphoblastic leuke-
mia cells from these mice in tissue culture.
Nilotinib acts by inhibiting the tyrosine kinase activity of
the Bcr/Abl protein, which is essential for Bcr/Abl medi-
ated oncogenic transformation [4-6]. As shown in Fig 4A
for one representative sample S9, the tyrosine kinase activ-
ity of Bcr/Abl was significantly inhibited 2 hours after
nilotinib treatment in vivo but was fully active 23 hours
after the treatment, as is evident from sample S5 (Fig. 4A)
based on immunoblotting of the lysates with an antibody
against phosphotyrosine.
In addition, we measured phosphorylation of the Crkl
protein, which is a substrate for the Bcr/Abl tyrosine
kinase. Tyrosine phosphorylated Crkl is distinguishable
from the non-tyrosine phosphorylated form because it
has retarded mobility on SDS-PAA gels. The ratio of phos-
phorylated to non-phosphorylated Crkl thus serves as an
independent indicator of Bcr/Abl tyrosine kinase activity.
As shown in Fig. 4C, higher levels of phosphorylated Crkl
were observed in the samples which showed high levels of
Bcr/Abl tyrosine kinase activity. In contrast, in the sample
(S9) showing reduction of tyrosine kinase activity, the lev-
els of non-phosphorylated Crkl were higher than those of
phosphorylated Crkl. SDS-SB lysates from both the paren-
tal cell line 8093 and two cell lines A-5 and A-21 estab-
lished from randomly selected nilotinib-treated mice were
also included for comparison. High levels of tyrosine
kinase activity were also observed in these cells (Fig.
4A,C). As controls, we included blotting with antibodies
for endogenous Bcr and P190 Bcr/Abl protein, and
GAPDH as loading control (Fig. 4B,D).
Amplification of the P210 Bcr/Abl gene has been previ-
ously reported to confer Imatinib-resistance in patients
[11,12,18-21]. We investigated whether the cell lines A-5
and A-21, isolated from mice that had developed leuke-
mia while on Nilotinib treatment, had BCR/ABL  gene
amplification as compared to the parental cell line 8093.
However, no differences were observed in the gene copy
number or protein levels (results not shown and Fig. 4B).
Western blot analysis of effect of nilotinib on the tyrosine  kinase activity of Bcr/Abl in vivo Figure 4
Western blot analysis of effect of nilotinib on the 
tyrosine kinase activity of Bcr/Abl in vivo. S-5 and S-9 
are lymphoma lysates prepared from two mice transplanted 
with 8093 cells in the nilotinib-treated group 23 hours and 2 
hours after the last nilotinib treatment respectively. Lanes A-
5, A-21 and 8093 contain lysates prepared from lymphoma 
cell lines A-5, A-21 and 8093. 8093 is the parental cell line 
and A-5, A-21 lymphoma cells were isolated from two mice 
in the nilotinib treatment group and cultured ex vivo. All 
leukemia cell lysates shown here are from mice, which devel-
oped lymphoma during Nilotinib treatment. Membranes 
were reacted with antibodies indicated below each panel. 
Arrows indicate the positions of P190 Bcr/Abl, P160 Bcr 
(endogenous mouse) and phosphorylated and non-phosphor-
ylated Crkl.Molecular Cancer 2007, 6:67 http://www.molecular-cancer.com/content/6/1/67
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Also, mutations in the kinase domain of Abl within Bcr/
Abl have been previously reported to confer Imatinib-
resistance in CML patients [11,13-21] and a recent study
showed that certain other mutations in Abl can make cells
nilotinib-resistant [29,30]. However we did not detect any
mutations in the Abl ATP binding pocket in DNA from the
A-5 and A-21 cell lines isolated from the nilotinib-treated
mice or in the parental 8093 cells (not shown).
Stromal protection against nilotinib treatment
To investigate whether the cells isolated from the nilo-
tinib-treated mice, A-5 and A-21 had any other cell-inher-
ent mechanism of resistance against nilotinib therapy, we
evaluated their in vitro ability to proliferate in the presence
of nilotinib. Interestingly, we did not observe any differ-
ence in the sensitivity of A-5 and A-21 towards nilotinib
as compared to 8093 (Fig. 5). We assessed the viability of
the three cell lines during treatment with 20 nM nilotinib
both in the presence and absence of stromal support (con-
sisting of a layer of mitotically inactivated mouse embry-
onic fibroblasts). All three cell lines behaved very
similarly: their viability dropped to less than 20% within
48 hours of 20 nM nilotinib treatment. However, we
obtained very different results in long-term cultures
between cells cultured with and without stroma. Their via-
bility without stroma in the presence of 20 nM nilotinib
progressively declined over the course of 3–4 days. By the
sixth day, viability was reduced to zero (Fig. 5B). In con-
trast, though the three cell lines cultured in the presence
of irradiated stroma experienced a drastic drop in viability
for the initial 4–5 days of treatment, the viability started
to improve by the sixth day of treatment. All three cell
lines recovered and had a viability of >60% on tenth day
of treatment (Fig. 5A). Thus the cells that were obtained
after the initial drop in viability were able to proliferate
and maintain good viability in the presence of 20 nM
nilotinib in vitro.
Resistance to Nilotinib is independent of Jak2 function
We next examined a possible mechanism leading to Bcr/
Abl-independent resistance to nilotinib. Samantha et al
[36] showed that Jak2 is an important target in CML, and
the Jak inhibitor AG490 was able to induce apoptosis in
cells that expressed imatinib-resistant mutants of Bcr/Abl.
Very recently, Wang et al [37] further implicated Jak2 in
Bcr/Abl-independent imatinib and nilotinib resistance
caused by GM-CSF production by myeloid leukemic cells.
Therefore, using the Jak inhibitor AG490, we investigated
if Jak2, in addition to its involvement in drug resistance of
myeloid leukemia cells, also contributes to resistance
development of lymphoid leukemia cells. As shown in
Fig. 6A, AG490 treatment significantly decreased the sur-
vival of the lymphoid leukemia cells in a dose-dependent
manner when these cells were co-cultured with MEFs.
Interestingly, AG490 treatment for 48 hours also affected
normal function of the feeder layer cells, as the prolifera-
tion of non-irradiated MEFs was severely reduced (more
than 4 times reduction in the presence of 50 µM AG490;
results not shown) compared to treatment with the vehi-
cle DMSO. Treatment of the Bcr/Abl lymphoblastic leuke-
mia cells with AG490 during (Fig. 6B) and after (Fig. 6C)
resistance development to nilotinib did not further affect
the survival, as compared to its effect on non-resistant
leukemia cells (Fig. 6A). Instead, in both experiments,
nilotinib-resistant lymphoblastic leukemia cells seemed
to also acquire additional resistance to AG490, though in
a dose dependent manner, as evidenced by the resump-
tion of growth after an initial drop in viability upon first
addition of AG490 (Fig. 6C).
Discussion
Nilotinib is a drug related to imatinib and that, based on
preclinical studies, shows great promise in the treatment
of Ph-positive leukemias. To date, the most extensive test-
ing has been for effect in models for P210 Bcr/Abl caused
CML and only a limited number of studies have examined
Ph-positive ALL cells. Weisberg et al [24] treated 32D cells
transfected with P190 with nilotinib and reported that it
is at least 10-fold more effective than imatinib in sup-
pressing proliferation of these cells. Verstovsek et al [26]
tested nilotinib against two human Ph-positive ALL cell
lines and reported that nilotinib was 30–40 times more
Long term viability of three lymphoma cell lines 8093, A-5  and A-21 treated with 20 nM nilotinib either in the presence  (A) or absence (B)of irradiated stroma (mouse E14.5 embry- onic fibroblasts) Figure 5
Long term viability of three lymphoma cell lines 
8093, A-5 and A-21 treated with 20 nM nilotinib 
either in the presence (A) or absence (B)of irradiated 
stroma (mouse E14.5 embryonic fibroblasts). 3 × 106 
lymphoma cells were seeded in 6 well tissue culture plates 
and treated with 20 nM nilotinib. Fresh drug was added every 
third day with the change of medium. Viability was assessed 
by the Trypan Blue exclusion method and is expressed as 
percentage of viable cells/total cells. Each point represents 
the average of triplicate values ± SEM.Molecular Cancer 2007, 6:67 http://www.molecular-cancer.com/content/6/1/67
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potent than imatinib. We also found that in vitro, nilotinib
is 10–25 fold more effective than imatinib in eradicating
P190 Bcr/Abl lymphoblasts. However, it is clear that a dif-
ferent sensitivity to this drug exists between the three
independent cell lines that we tested which were derived
from the same transgenic Bcr/Abl strain, but from differ-
ent individuals in a different genetic background.
The effect of nilotinib on lymphoblastic leukemia has not
been examined in mouse models. We used two different
models to address this. In the transgenic mouse model,
treatment was sufficient to eradicate very large numbers of
leukemia cells in the lymph nodes within a single week.
FACS analysis showed that numbers of circulating leuke-
mic cells were also greatly reduced after treatment for this
period of time. Indeed, treatment for 30 days may have
been sufficient to cure two of the five mice of the first
leukemia. Since these mice are Bcr/Abl transgenic, they
can not be cured definitively and the finding that the mice
succumbed to leukemia about 50 days later could repre-
sent the emergence of a second, independent leukemia.
In the second model, we transplanted a low number of
previously cultured leukemia cells into compatible
C57Bl/6J mice, which are congenic with the 8093 cells.
The 8093 cells were isolated from an animal with terminal
leukemia and can thus be considered to represent the final
stages in the evolution of the leukemia in that animal.
These cells appear to be highly malignant and within 21
days only 10,000 cells were needed to reproducibly cause
terminal leukemia in all transplant recipients. Survival of
the nilotinib-treated animals was significantly longer and
we conclude that nilotinib is also very effective against
these highly malignant cells in vivo.
However, in both the transplant model and the transgenic
model, animals did die of leukemia after we stopped treat-
ment and the relapse was relatively rapid (less than 2
weeks). There were also transplanted mice that developed
leukemia while on treatment. Therefore, in these models,
nilotinib did not provide a cure for P190 Bcr/Abl caused
ALL. This result is of interest in the context of a phase I
clinical trial that included 13 patients with Ph-positive
ALL, [25], in which one patient showed a partial hemato-
logical response and one a complete molecular remission,
indicating that the drug was, overall, not highly effective
in this type of leukemia.
The question therefore remains why Ph-positive ALL over-
all responds less well to Bcr/Abl tyrosine kinase inhibitors
including imatinib and nilotinib. Our results do not sup-
port the view that subclones harboring point mutations in
the Abl kinase domain are rapidly selected out. Our stud-
ies do suggest that drug levels may be an important factor.
We saw a clear inhibition of P190 Bcr/Abl tyrosine kinase
activity at 2 hours but not at 23 hours after the last treat-
ment with nilotinib, indicating that in these mice, the
drug concentration in plasma at 23 hours was insufficient
to fully inhibit the P190 Bcr/Abl. Weisberg et al [24] meas-
ured plasma levels of nilotinib in mice and reported that
at 75 mg/kg, nilotinib concentrations of 29 and 2.5 µM
were present in their plasma at 2 and 24 hours. Kantarjian
et al [25] measured trough levels of nilotinib between 1
Effect of Jak inhibitor AG490 on survival of nilotinib-insensi- tive cells in the presence of stroma Figure 6
Effect of Jak inhibitor AG490 on survival of nilotinib-
insensitive cells in the presence of stroma. 3 × 106 lym-
phoma cells were seeded in 6 well tissue culture plates with 
irradiated MEFs and further treated with 5, 50 or 100 µM 
AG490 (A) or 20 nM nilotinib (B, C), respectively. In (B) and 
(C), in addition to nilotinib, treatment with 5, 50 or 75 µM 
AG490 was initiated as indicated by an arrow. As a control 
for the effect of AG490, single treatment with DMSO only 
(A) or 20 nM nilotinib (B, C) was analyzed, respectively. 
Fresh drug was added (depending on proliferation of the 
leukemia cells) every second or third day with the change of 
medium. Viability was assessed by propidium iodide uptake 
using a FACScan. Each point represents the average of tripli-
cate values ± SEM.Molecular Cancer 2007, 6:67 http://www.molecular-cancer.com/content/6/1/67
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and 2.3 µM nilotinib in humans. Our transgenic construct
was generated using human BCR and ABL gene segments
and will therefore encode a protein that is identical to the
P190 Bcr/Abl found in human Ph-positive ALL. Thus,
even with the highest dose of nilotinib, (600 mg twice
daily) in humans, there is a period in which the levels
approach those which were unable to fully inhibit the
human P190 Bcr/Abl protein in vivo in the mice.
We speculate, that in the mice, a residual population of
leukemic cells remains, and that over a 24-hour period, as
the drug concentration starts to decrease during the later
hours after administration, these residual resume prolifer-
ation. Over a period of time, this results in a slow increase
in the tumor burden.
Ex vivo, stroma was able to provide protection to these
cells as well as the original parent cells when we treated
them with a moderate 20 nM dose of nilotinib. This out-
come is similar to results obtained using other therapeutic
drugs including imatinib, K25 and SCH66336 [38-40] in
such cells and suggests that the microenvironment pro-
vides very pronounced pro-survival support in vivo when
lymphoblastic leukemia cells experience waxing and wan-
ing drug concentrations in the course of daily treatment.
Other investigators have demonstrated that Jak is
involved in the transformation caused by Bcr/Abl [i.e.,
[41,42]; review, [43]]. The Jak family of kinases is
involved in transducing signals from a number of recep-
tors for cytokines including GM-CSF, Il-3, Il-7 and SDF-1α
[44-47]. Interestingly, Wang et al [37] identified autose-
cretion of GM-CSF as a mechanism that allowed CML cells
to resist imatinib and nilotinib treatment in vitro. They
further used an inhibitor for Jak, AG490, to show that this
was mediated by Jak. Xie et al [42] reported that in the
presence of IL-3, Bcr/Abl-expressing cells become resistant
to imatinib but that AG490 could overcome this. A similar
Bcr/Abl-independent mechanism of imatinib resistance
was reported by Williams et al. [48], who found that Il-7
increased resistance of mouse Arf-/-, p210 Bcr/Abl pre-B
cells to imatinib. AG490 was able to overcome this as
well. Therefore, we tested if the inhibitor AG490 is able to
re-sensitize cells to nilotinib. We found that the survival of
the leukemia cells was significantly affected by treatment
with AG490 alone. However, AG490 could not overcome
nilotinib-resistance unless used in relatively high doses of
75 to 100 µM, which eradicated resistant as well as non-
resistant cells similarly. Furthermore, besides leukemia
cells, AG490 treatment also affected function of the feeder
layer cells, thereby suggesting potential appearance of
side-effects if used in combined therapy with nilotinib.
Conclusion
We conclude that nilotinib holds great potential for ther-
apeutic use in the treatment of Ph+ leukemias, but that, as
in some of the mice, response may be relatively short in
humans. Our studies show that nilotinib is highly effec-
tive and clearly superior to imatinib, and can eliminate
large numbers of lymphoblastic leukemia cells in vivo. We
found that nilotinib was able to completely eliminate the
cells in vitro even in the presence of protective stroma
when a sufficiently high dose was applied. However, these
circumstances are probably never attainable in a human
patient in whom drug delivery is much more complicated
than adding a drug to the medium of cultured cells. If
individual patients could be monitored for a continu-
ously high level of drug and for inhibition of the Bcr/Abl
tyrosine kinase activity, and if the drug dose could be
adapted in individual patients to optimize this, it might
be possible to eradicate the entire leukemic clone.
Methods
Mouse model and cell lines
The P190 Bcr/Abl transgenic mouse model has been pre-
viously described [33,34]. On a C57Bl/6J background,
average age at death for the f10–f15 generation (n = 127)
was 100 days (range 38–265 days). The 8093 lymphoblas-
tic leukemia cell line was established from a P190 Bcr/Abl
transgenic mouse on a C57Bl/6J (f11) background as
described previously [49]. B-1 and B-2 lymphoblastic
leukemia cells have been previously described [50]. Lym-
phoblastic leukemia cell lines A-5 and A21 were estab-
lished from nilotinib-treated C57Bl/6J mice transplanted
with 8093 cells. The cells were grown in complete lym-
phoblast medium consisting of McCoy's 5A medium (Life
Technologies, Inc., Rockville, MD) supplemented with
15% heat inactivated FCS, 110 mg/L sodium pyruvate, 2
mmol/L L-glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin, 10 ng/ml recombinant IL-3 (Calbiochem,
San Diego, CA) and 50 µmol/L β-mercaptoethanol in the
presence of E14.5 irradiated mouse embryonic fibroblasts
(MEFs) [51].
All animal research was performed at the Animal Care
Facility of the Research Institute of Childrens Hospital Los
Angeles in accordance with institutional guidelines. Ani-
mals were maintained in accordance with the NIH Guide
for the care and use of Laboratory Animals.
Treatment of lymphoblastic leukemia cells with Nilotinib, 
imatinib or AG490
Nilotinib was obtained from Novartis Pharmaceuticals
(Basel, Switzerland). AG490 was purchased from Calbio-
chem (San Diego, USA). The parental lymphoblastic
leukemia cell line 8093 and the A-5 and A-21 cell lines
were seeded in wells of a 6-well plate (3 × 106 cells/well)
either in the presence or absence of E14.5 irradiated MEFsMolecular Cancer 2007, 6:67 http://www.molecular-cancer.com/content/6/1/67
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as described [49]. Samples in triplicate wells were treated
either with 20, 50, 100, or 200 nM nilotinib or 5 µM imat-
inib or DMSO as control. In additional pilot experiments,
8093 cells were treated with 100, 75, 50 and 5 µM AG490
while cultured on MEFs. The cell viability in control exper-
iments was consistently above 80%. Drug in the experi-
mental wells was added every second or third day along
with the fresh change of medium dependent on prolifera-
tion of the treated cells. Aliquots were removed from each
individual well and cell viability was determined using
the Trypan Blue exclusion method. Viability is expressed
as percentage of the number of Trypan Blue excluding
cells divided by the number of total cells. In the case of
AG490 treatment, viability was measured by propidium
iodide uptake using a FACScan (BD Biosciences, San Jose,
USA). Each data point is represented as mean ± SEM of
triplicate samples.
Treatment with nilotinib in a transplant model
Fifteen C57Bl/6J mice (male, 6 weeks old, Jackson Lab,
Bar Harbor, Maine) were transplanted with 1 × 104 8093
cells via a tail vein injection. Five days later, mice were ran-
domly selected for vehicle or nilotinib treatment. Eight
mice (vehicle group) were fed a mixture of 8 parts peanut
butter and two parts vegetable oil and the remaining
seven mice (treatment group) were treated with 75 mg of
nilotinib/kg body weight added to the same peanut/oil
mixture daily. Treatment was stopped 50 days after day 1
of transplantation.
Analysis of leukemia regression in transgenic mice treated 
with nilotinib
Peripheral blood of preleukemic and overtly leukemic
P190 transgenic mice as well as wild-type littermates was
examined by flow cytometry using a FACScan (BD Biosys-
tems, Heidelberg, Germany) to identify markers suitable
to detect the leukemic cells. Peripheral blood of three
additional P190 transgenic animals that had developed
overt leukemia/lymphoma was analyzed before and after
seven days of treatment with nilotinib as described above.
After erythrocyte lysis, cells were stained with antibodies
against mouse CD19 and AA4.1 (BD Biosciences, San
Jose, CA). In addition, five P190 Bcr/Abl transgenic mice
with visible signs of lymphoma were selected at different
time points and treated with 75 mg/kg nilotinib as
described above. Treatment was continued for 30 days.
Western blot analysis
Animals that had been transplanted with 8093 cells in the
nilotinib-treated group and that started showing signs of
ALL were sacrificed either 2 hours or 23 hours after the
daily administration of 75 mg/kg of nilotinib. SDS-SB
lysates of lymphoma tissue were prepared and lymphob-
lastic leukemia cell lines were isolated from these mice.
Two cell lines, A-5 and A-21, were subsequently used for
further experiments. SDS-SB lysates from lymphoma tis-
sues and lymphoblastic leukemia cell lines were run on
7.5% SDS-PAA gels (for detection of phosphotyrosine and
Bcr) and 15% SDS-PAA gels (for Crkl detection). Mem-
branes were reacted with PY-20-Horseradish peroxidase
(1:2500, BD Transduction Laboratories, CA), Bcr N-20
(1:500, Santa Cruz Biotechnology, CA), Crkl (1:1000, H-
62, Santa Cruz Biotechnology), or GAPDH (1:5000,
Chemicon International, CA) antibodies using standard
procedures.
Bcr/Abl gene copy number and point mutations
BCR/ABL gene copy number was assessed using Southern
blotting of Bam HI digested genomic DNA isolated from
the parental cell line 8093 and the lymphoma derived cell
lines A-5 and A-21. To examine the ABL segment in BCR/
ABL  for mutations, a 417 bp region from the DNA of
8093, A-5 and A-21 was amplified using forward primer
5'-agagatcaaacaccctaacct-3' and reverse primer 5'-gcattt-
ggagtattgctttgg-3' and sequenced. This region includes
nucleotides 876–1293 (residues 293–462) of c-Abl
(NM_005157) containing point mutations T315, F317,
M351, Q252 and H396 detected in human patients [20].
A larger region of 675 bp including both the ATP binding
pocket and the activation loop was also amplified and
sequenced using primers AN4+ 5'-tggttcatcatcattcaacg-
gtgg-3' and A7- 5'-agacgtcggacttgatggagaact-3' as described
by Sacha et al [52].
Statistical analysis
The Log rank test was used to test the significance of sur-
vival. A p-value of less than 0.05 was considered to be sig-
nificant.
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